Literature DB >> 9716869

Aspirin, nonsteroidal anti-inflammatory drugs, and epistaxis. A regional record linkage case control study.

H L Tay1, J M Evans, A D McMahon, T M MacDonald.   

Abstract

To assess the relationship between nonsteroidal anti-inflammatory drugs (NSAIDs) and spontaneous epistaxis in adults over 50 years old, a case control study was carried out by using a record linkage database for the population of Tayside, Scotland, which included 319,465 people. The study group consisted of 326 patients who were hospitalized with epistaxis between May 1989 and December 1992, but who had not previously been hospitalized with this diagnosis. Six community controls and 4 hospital controls, matched for age and sex to each case, were used. Previous exposure to prescribed aspirin and other NSAIDs was investigated. There was a significant association between aspirin exposure and epistaxis when either community or hospital controls were used (p < .001). Patients who had aspirin prescriptions had a relative risk of hospital admission for epistaxis of between 2.17 and 2.75, depending on the control group used. No association between non-aspirin NSAIDs and epistaxis was evident with either control group.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9716869     DOI: 10.1177/000348949810700808

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  8 in total

1.  Adverse drug reactions as cause of admission to hospital: admissions to ear, nose, and throat departments were not mentioned.

Authors:  Nicholas J Calder; Duncan MacDonald
Journal:  BMJ       Date:  2004-08-21

Review 2.  [Current aspects in epistaxis].

Authors:  B J Folz; M Kanne; J A Werner
Journal:  HNO       Date:  2008-11       Impact factor: 1.284

Review 3.  Aetiological profile and treatment outcomes of epistaxis at a major teaching hospital: a review of 721 cases.

Authors:  Brian Carey; Patrick Sheahan
Journal:  Ir J Med Sci       Date:  2017-12-02       Impact factor: 1.568

4.  The long-term fate of epistaxis patients with exposure to antithrombotic medication.

Authors:  Rafael R Stadler; Rahel Kindler; David Holzmann; Michael B Soyka
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-02-09       Impact factor: 2.503

Review 5.  Epistaxis: an update on current management.

Authors:  L E R Pope; C G L Hobbs
Journal:  Postgrad Med J       Date:  2005-05       Impact factor: 2.401

6.  Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity.

Authors:  S V Morant; A D McMahon; J G F Cleland; P G Davey; T M MacDonald
Journal:  Br J Clin Pharmacol       Date:  2004-02       Impact factor: 4.335

7.  Hemorrhage-adjusted iron requirements, hematinics and hepcidin define hereditary hemorrhagic telangiectasia as a model of hemorrhagic iron deficiency.

Authors:  Helen Finnamore; James Le Couteur; Mary Hickson; Mark Busbridge; Kevin Whelan; Claire L Shovlin
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

8.  Is chronic obstructive pulmonary disease a risk factor for epistaxis after coronary artery bypass graft surgery?

Authors:  Faruk Cingoz; Bilgehan Savas Oz; Gokhan Arslan; Adem Guler; Mehmet Ali Sahin; Celalettin Gunay; Mehmet Arslan
Journal:  Cardiovasc J Afr       Date:  2014-11-10       Impact factor: 1.167

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.